Leucine plus chemoradiation before surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding leucine (a simple amino acid) to standard chemoradiation before surgery can help shrink rectal cancer and improve outcomes. It is for people with locally advanced rectal cancer that hasn't yet spread to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have rectal cancer that is locally advanced (stage T3 or higher, or spread to nearby lymph nodes) and the tumor is within 10 cm of the anal opening.
- You have not already received standard treatments for rectal cancer (like chemo or radiation).
- You are generally active and able to take care of yourself (ECOG 0-1).
- Your blood tests show good kidney, liver, and bone marrow function.
- You do not have other serious medical conditions like heart disease, active infections, autoimmune disorders, or a history of other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
This trial compares two approaches for early-stage rectal cancer: chemotherapy plus local surgery versus standard chemoradiotherapy. It aims to see if less intensive treatment can work just as well, reducing side effects.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial compares different combinations of chemotherapy drugs given before surgery to the standard approach of chemoradiation (chemotherapy plus radiation) for rectal cancer that has not spread. The goal is to see if the drug combinations are more effective at shrinking tumors and improving outcomes.
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.